Intragastric Balloons Market

Intragastric Balloons Market Forecast and Outlook 2025 to 2035

The global intragastric balloons market is projected to grow from USD 0.14 billion in 2025 to approximately USD 0.42 billion by 2035, registering an absolute increase of USD 0.28 billion over the forecast period. This represents a total growth of 200%, with the market expected to expand at a CAGR of 11.6% between 2025 and 2035. Market expansion will be supported by the growing prevalence of obesity worldwide, the rising preference for minimally invasive weight-loss procedures, and an increasing focus on non-surgical bariatric interventions in both developed and emerging healthcare systems.

Between 2025 and 2030, the intragastric balloons market is projected to expand from USD 0.14 billion to USD 0.27 billion, an increase of USD 0.13 billion, representing approximately 46.4% of the total expected growth for the decade. During this phase, demand will be driven by rising patient preference for reversible and temporary obesity treatment options, as well as expanding adoption of non-surgical bariatric procedures within hospitals and ambulatory surgical centers.

Quick Stats for Intragastric Balloons Market

• Intragastric Balloons Market Value (2025): USD 0.14 billion
• Intragastric Balloons Market Forecast Value (2035): USD 0.42 billion
• Intragastric Balloons Market Forecast CAGR: 11.6%
• Leading Balloon Type in Intragastric Balloons Market: Single (74.0%)
• Key Growth Regions in Intragastric Balloons Market: Asia Pacific, North America, and Europe
• Key Players in Intragastric Balloons Market: Apollo Endosurgery Inc., Obalon Therapeutics Inc., Allurion Technologies Inc., ReShape Medical Inc., Spatz3, Helioscopie, MEDSIL, Endalis, Lexel Medical, Silimed, BioEnterics

Healthcare providers are broadening their service portfolios to include endoscopic weight-loss treatments that offer lower complication risks, shorter recovery times, and improved patient compliance. Emerging markets in Asia Pacific, Latin America, and the Middle East are witnessing increased availability of these procedures due to expanding healthcare infrastructure and growing awareness of lifestyle-related disorders.

From 2030 to 2035, the market is forecast to grow from USD 0.27 billion to USD 0.42 billion, adding USD 0.15 billion and accounting for roughly 53.6% of total decade-long growth. This stage will likely be marked by the expansion of dedicated bariatric and metabolic treatment centers, adoption of next-generation balloon systems, and refinement of treatment protocols focused on personalized care.

Manufacturers are expected to introduce devices with improved material durability, enhanced filling mechanisms, and adjustable volume control to optimize patient outcomes and reduce complications. The broader adoption of standardized clinical safety protocols and post-procedure monitoring systems will further reinforce market confidence in intragastric balloon therapy as a viable alternative to surgical bariatric solutions.

Between 2020 and 2025, the intragastric balloons market experienced consistent growth as clinical practices increasingly incorporated minimally invasive obesity management methods. Rising global awareness of obesity-related comorbidities and advancements in endoscopic technologies contributed to a shift from surgical to non-surgical weight-loss interventions. Hospitals and specialty clinics expanded their bariatric treatment programs to meet the growing demand for temporary and less invasive options, particularly among patients ineligible for or unwilling to undergo surgery.

Research and development efforts during this period focused on improving procedural safety, patient comfort, and balloon efficacy. Innovations in biocompatible materials, dual-balloon systems, and real-time imaging guidance enhanced both performance and clinical outcomes. These developments established a technological foundation for the next phase of growth, characterized by continued device optimization, digital patient monitoring integration, and wider acceptance of non-invasive weight management therapies.

Through 2035, the intragastric balloons market is expected to remain on a steady upward trajectory, shaped by technological advancement, expanding clinical acceptance, and an evolving focus on patient-centric care. As healthcare systems emphasize preventive and minimally invasive treatment approaches, intragastric balloon systems are anticipated to play an increasingly important role in comprehensive obesity management worldwide.

Intragastric Balloons Market Key Takeaways

Metric	Value
Estimated Value in (2025E)	USD 0.14 billion
Forecast Value in (2035F)	USD 0.42 billion
Forecast CAGR (2025 to 2035)	11.6%

Why is the Intragastric Balloons Market Growing?

Market expansion is being supported by the increasing prevalence of obesity and the corresponding need for effective non-surgical weight management solutions in clinical applications across global healthcare and medical operations.

Modern healthcare providers are increasingly focused on advanced intragastric balloon systems that can improve treatment efficacy, reduce surgical complications, and enhance patient satisfaction while meeting stringent safety requirements. The proven efficacy of intragastric balloons in various bariatric applications makes them an essential component of comprehensive obesity management strategies and clinical programs.

The growing emphasis on healthcare transformation and minimally invasive procedure optimization is driving demand for ultra-efficient intragastric balloons that meet stringent performance specifications and safety requirements for patient applications.

Healthcare providers' preference for reliable, high-performance products that can ensure consistent treatment outcomes is creating opportunities for innovative balloon technologies and customized bariatric solutions.

The rising influence of clinical guidelines and regulatory protocols is also contributing to increased adoption of premium-grade intragastric balloons across different medical applications and healthcare systems requiring advanced therapeutic technology.

Opportunity Pathways - Intragastric Balloons Market

The intragastric balloons market represents a specialized growth opportunity, expanding from USD 0.14 billion in 2025 to USD 0.42 billion by 2035 at a 11.6% CAGR. As healthcare providers prioritize treatment efficacy, safety compliance, and patient outcomes in complex bariatric processes, intragastric balloon systems have evolved from a niche medical technology to an essential component enabling weight management, metabolic optimization, and multi-stage clinical treatment across healthcare operations and specialized medical applications.

The convergence of obesity epidemic expansion, increasing minimally invasive procedure adoption, specialized bariatric center growth, and regulatory requirements creates momentum in demand. High-quality formulations offering superior treatment performance, cost-effective endoscopic systems balancing performance with economics, and specialized filling material variants for critical applications will capture market premiums, while geographic expansion into high-growth Asian healthcare markets and emerging market penetration will drive volume leadership. Healthcare emphasis on patient safety and treatment reliability provides structural support.

Segmental Analysis

The market is segmented by balloon type, administration, filling material, end use, and region. By balloon type, the market is divided into single, dual, and triple. Based on administration, the market is categorized into endoscopy and pill form.

By filling material, the market is divided into saline-filled and gas-filled. By end use, the market is segmented into hospitals, ambulatory surgical centers, and clinics. Regionally, the market is divided into Asia Pacific, North America, Europe, Latin America, Middle East & Africa.

Which Intragastric Balloon Type exhibits Dominance in the Market?

Single intragastric balloons account for 74.0% of the market share in 2025. Healthcare providers increasingly recognize the optimal balance of efficacy and safety offered by single balloon systems for most bariatric applications, particularly in weight management and clinical treatment processes. This balloon type addresses both performance requirements and economic considerations while providing reliable outcomes across diverse patient applications.

This balloon type forms the foundation of most clinical protocols for obesity treatment applications, as it represents the most widely accepted and commercially viable configuration of intragastric balloons in the industry. Safety control standards and extensive clinical testing continue to strengthen confidence in single balloon formulations among healthcare and bariatric providers. With increasing recognition of the cost-performance optimization requirements in medical operations, single balloon systems align with both operational efficiency and patient care goals, making them the central growth driver of comprehensive bariatric strategies.

By Administration, Which Category Makes Maximum Use of Intragastric Balloons?

Endoscopic administration is projected to represent 70.0% of intragastric balloon demand in 2025. Healthcare providers recognize that endoscopic procedures, including complex placement processes, specialized monitoring needs, and multi-stage clinical systems, often require advanced balloon technologies that standard insertion methods cannot adequately provide. Endoscopic administration offers enhanced procedural control and safety compliance in hospital and specialized center applications.

The segment is supported by the established nature of endoscopic adoption, requiring sophisticated medical systems, and the increasing recognition that advanced balloon placement can improve treatment performance and patient outcomes. Healthcare providers are increasingly adopting evidence-based clinical guidelines that recommend specific endoscopic procedures for optimal treatment results. As understanding of bariatric complexity advances and safety requirements become more stringent, endoscopic administration will continue to play a crucial role in comprehensive obesity management strategies within the medical market.

Why are Saline-filled Intragastric Balloons Preferred by Healthcare Providers?

Saline-filled balloons are projected to represent 71.0% of intragastric balloon demand in 2025. Healthcare providers recognize that saline-based systems, including biocompatible fluid properties, established safety profiles, and reliable deflation mechanisms, often require proven balloon technologies that alternative filling materials cannot adequately provide. Saline-filled balloons offer enhanced safety assurance and clinical reliability in hospital and ambulatory surgical center applications.

Saline-filled balloons usage is supported by the mature nature of saline technology adoption, requiring established manufacturing systems, and the increasing recognition that saline-filled balloons can improve patient safety and treatment outcomes. Healthcare providers are increasingly following evidence-based medical guidelines that recommend specific saline-filled systems for optimal procedural results. As understanding of device safety advances and regulatory requirements become more stringent, saline-filled balloons will continue to play a crucial role in comprehensive bariatric treatment strategies within the clinical market.

Which End Use Category Dominates in the Global Intragastric Balloons Market?

By end use, hospitals are projected to represent 45.0% of intragastric balloon demand in 2025. Healthcare administrators recognize that hospital settings, including comprehensive medical facilities, specialized bariatric departments, and multi-disciplinary clinical teams, often require advanced balloon systems that outpatient facilities cannot adequately provide. Hospital-based procedures offer enhanced patient monitoring and complication management capabilities in acute care applications.

The segment is supported by the established infrastructure of hospital adoption, requiring sophisticated medical systems, and the increasing recognition that hospital-based balloon placement can improve procedural safety and patient outcomes. Additionally, healthcare providers are increasingly implementing evidence-based protocols that prioritize hospital settings for optimal treatment delivery. As understanding of patient complexity advances and safety requirements become more comprehensive, hospitals will continue to play a crucial role in intragastric balloon deployment strategies within the healthcare market.

What are the Drivers, Restraints, and Key Trends of the Intragastric Balloons Market?

The intragastric balloons market is advancing steadily due to increasing recognition of non-surgical obesity treatment importance and growing demand for minimally invasive weight management solutions across the healthcare and medical sectors.

The market faces challenges, including complex procedural requirements, potential for device-related complications during placement and removal, and concerns about long-term efficacy for specialized patient populations. Innovation in balloon technologies and customized clinical protocols continues to influence product development and market expansion patterns.

Expansion of Specialized Bariatric Centers and Balloon Technologies

The growing adoption of specialized bariatric facilities is enabling the development of more sophisticated intragastric balloon placement and patient monitoring systems that can meet stringent safety requirements. Specialized medical centers offer comprehensive bariatric programs, including advanced endoscopic procedures and follow-up management processes that are particularly important for achieving optimal weight-loss outcomes in obesity treatment applications. Advanced healthcare facilities provide access to premium balloon technologies that can optimize treatment performance and reduce complication risks while maintaining cost-effectiveness for large-scale healthcare operations.

Integration of Digital Health Systems and Patient Management Platforms

Modern healthcare organizations are incorporating digital technologies such as real-time patient monitoring, automated compliance tracking systems, and telemedicine integration to enhance intragastric balloon treatment and follow-up processes. These technologies improve treatment adherence, enable continuous patient monitoring, and provide better coordination between healthcare providers and patients throughout the weight-loss cycle. Advanced digital platforms also enable customized treatment protocols and early identification of potential complications or device issues, supporting reliable clinical outcomes.

Analysis of the Intragastric Balloons Market by Key Countries

Country	CAGR (2025-2035)
India	13.1%
China	12.8%
USA	11.5%
Germany	10.9%
Brazil	10.6%
Japan	10.3%
UK	9.8%

The intragastric balloons market is experiencing varied growth globally, with India leading at a 13.1% CAGR through 2035, driven by rising obesity prevalence, expanding middle-class healthcare access, and growing domestic demand for affordable non-surgical weight-loss solutions. China follows at 12.8%, supported by rapid adoption of minimally invasive weight-loss options, growing recognition of obesity management importance, and expanding bariatric procedure capacity. Brazil records 10.6% growth, with a focus on developing private clinic networks and metabolic disorder treatment industries.

The USA shows 11.5% growth, representing technological innovations, insurance expansion coverage, and DTC awareness campaigns. Germany demonstrates 10.9% growth, emphasizing early device adoption and favorable regulatory standards. The UK records 9.8% growth with NHS and private sector demand for reversible treatments, while Japan shows 10.3% growth, representing an aging population with high metabolic disorder prevalence.

Why does India Demonstrate Growing Market Potential with Healthcare Access Expansion?

The intragastric balloons market in India is projected to exhibit robust growth with a CAGR of 13.1% through 2035, driven by ongoing obesity epidemic expansion and increasing recognition of minimally invasive weight-loss procedures as essential healthcare solutions for complex patient management processes. The country's expanding middle-class population and growing availability of specialized bariatric capabilities are creating significant opportunities for intragastric balloon adoption across both urban and tier-two city healthcare facilities.

Major international and domestic medical device companies are establishing comprehensive distribution and clinical support networks to serve the growing population of hospitals and bariatric centers requiring effective non-surgical obesity treatment solutions across patient and metabolic disorder management applications throughout India's major metropolitan areas.

The Indian government's strategic emphasis on healthcare infrastructure development and non-communicable disease management is driving substantial investments in specialized medical device capabilities. This policy support, combined with the country's large diabetic and obese patient population and expanding medical tourism requirements, creates a favorable environment for the intragastric balloons market development. Indian healthcare providers are increasingly focusing on cost-effective medical technologies to improve treatment outcomes, with intragastric balloons representing a key component in this obesity management transformation.

How will Increasing Preference for Minimally Invasive Surgeries widen prospects for Intragastric Balloons Demand in China?

The intragastric balloons market in China is expanding at a CAGR of 12.8%, supported by increasing healthcare accessibility, growing obesity awareness, and developing bariatric treatment infrastructure across the country's major urban clusters. The country's large patient population and increasing recognition of non-surgical weight-loss options are driving demand for effective minimally invasive clinical solutions in both hospital and private clinic applications.

International medical device companies and domestic manufacturers are establishing comprehensive distribution channels to serve the growing demand for advanced intragastric balloon systems while supporting the country's position as an emerging obesity treatment technology market.

China's healthcare sector continues to benefit from favorable regulatory policies, expanding private hospital capabilities, and cost-competitive medical device manufacturing infrastructure development. The country's focus on becoming a global healthcare innovation hub is driving investments in specialized bariatric technology and clinical infrastructure. This development is particularly important for intragastric balloon applications, as healthcare providers seek reliable domestic sources for critical medical devices to reduce import dependency and improve supply chain security.

How will the Intragastric Balloons Landscape Evolve in Brazil?

The intragastric balloons market in Brazil is projected to exhibit strong growth with a CAGR of 10.6% through 2035, driven by expanding private clinic networks and metabolic disorder management capabilities. The country's growing middle-class population and increasing obesity prevalence are creating significant opportunities for intragastric balloon adoption across both private and public healthcare markets. Brazilian medical providers are leveraging their established bariatric surgery expertise to integrate non-surgical weight-loss alternatives while supporting the country's position as a regional obesity treatment leader.

The Brazilian market benefits from favorable private healthcare investment, expanding bariatric procedure expertise, and growing patient awareness of minimally invasive options. This development is particularly important for intragastric balloon applications, as healthcare providers seek effective alternatives to permanent surgical procedures to serve diverse patient populations in urban markets.

What is the Outlook for the Intragastric Balloons Market in the USA?

The USA's advanced medical device market demonstrates sophisticated clinical deployment with documented intragastric balloon effectiveness in specialized bariatric departments and obesity treatment centers through integration with existing healthcare systems and insurance infrastructure.

The country leverages medical innovation expertise in technological device development and insurance expansion to maintain an 11.5% CAGR through 2035. Healthcare centers, including major metropolitan bariatric programs, showcase premium installations where intragastric balloon systems integrate with comprehensive electronic health record systems and patient management platforms to optimize treatment accuracy and clinical workflow effectiveness.

American healthcare providers prioritize device safety and regulatory compliance in obesity treatment development, creating demand for FDA-approved products with advanced features, including biocompatible materials validation and integration with USA clinical standards. The market benefits from established medical device infrastructure and a willingness to invest in innovative technologies that provide long-term patient benefits and compliance with healthcare regulations.

How will Germany’s Intragastric Balloons Market Assume Shape?

Germany's market expansion benefits from diverse bariatric surgery demand, including obesity treatment modernization in Berlin and Munich, early device adoption programs, and government healthcare programs that increasingly incorporate intragastric balloon solutions for non-surgical weight management applications. The country maintains a 10.9% CAGR through 2035, driven by rising metabolic syndrome awareness and increasing adoption of minimally invasive benefits, including superior safety profiles and reduced hospitalization requirements.

Market dynamics focus on high-quality intragastric balloons that balance advanced safety features with clinical effectiveness considerations important to German healthcare operators. Growing bariatric infrastructure creates demand for modern obesity treatment systems in new medical facilities and healthcare equipment modernization projects.

Why is the UK an Important Country for the Intragastric Balloons Market’s Expansion?

The UK's market expansion benefits from diverse obesity management demand, including NHS coverage expansion and private sector bariatric service growth. The country maintains a 9.8% CAGR through 2035, driven by rising demand for reversible obesity treatments and increasing preference for non-surgical weight-loss interventions through both public and private healthcare channels. The market prioritizes advanced features, including proven safety validation and integration with comprehensive clinical protocols that reflect UK healthcare expectations for efficacy and patient protection.

British healthcare providers focus on evidence-based treatment in obesity management development, creating demand for clinically validated intragastric balloons with advanced features including comprehensive patient monitoring and long-term outcome documentation. The market benefits from established clinical research infrastructure and investment in bariatric technology that provides sustainable patient benefits.

How does Emphasis on Precision and Quality Excellence Influence Growth in Japan?

Japan demonstrates steady market development with a 10.3% CAGR through 2035, distinguished by healthcare providers' preference for high-quality intragastric balloons that integrate seamlessly with existing medical equipment and provide reliable long-term efficacy in specialized clinical applications.

The market prioritizes advanced features, including precision manufacturing standards, comprehensive safety validation, and integration with sophisticated patient monitoring platforms that reflect Japanese healthcare expectations for technological superiority and operational excellence.

Japanese healthcare providers focus on device reliability and procedural precision in obesity management development, creating demand for premium intragastric balloons with advanced features including automated safety monitoring and comprehensive clinical support. The market benefits from established medical research infrastructure and investment in proven technology that provides long-term metabolic health benefits for the aging population.

Europe Market Split by Country

The intragastric balloons market in Europe is projected to grow from USD 0.04 billion in 2025 to USD 0.11 billion by 2035, registering a CAGR of 10.5% over the forecast period. Germany is expected to maintain its leadership position with a 27.5% market share in 2025, rising to 28.2% by 2035, supported by its advanced bariatric infrastructure, favorable regulatory framework, and strong clinical research presence throughout major medical regions.

France follows with a 21.3% share in 2025, projected to reach 21.8% by 2035, driven by comprehensive obesity management protocols, medical innovation integration, and expanding specialty bariatric networks serving both domestic and international patient populations. The UK holds a 19.7% share in 2025, expected to increase to 20.1% by 2035, supported by NHS coverage expansion and growing private sector adoption.

Italy commands a 13.2% share in 2025, projected to reach 13.6% by 2035, while Spain accounts for 10.8% in 2025, expected to reach 11.1% by 2035. The rest of Europe region, including Nordic countries, Eastern Europe, and smaller Western European markets, is anticipated to hold 7.5% in 2025, declining slightly to 5.2% by 2035, attributed to market consolidation toward larger core markets with established bariatric and clinical capabilities.

How is the Emphasis on Advanced Medical Technology Integration driving Intragastric Balloons Usage in South Korea?

South Korea demonstrates strong market development with a 11.2% CAGR through 2035, distinguished by healthcare providers' preference for technologically advanced intragastric balloons that integrate seamlessly with digital health platforms and provide comprehensive patient monitoring capabilities in specialized obesity treatment applications.

The market prioritizes cutting-edge features, including smart balloon technology, real-time tracking systems, and integration with comprehensive telemedicine platforms that reflect Korean healthcare expectations for technological innovation and clinical excellence.

South Korean healthcare providers focus on digital integration and procedural efficiency in obesity management development, creating demand for next-generation intragastric balloons with advanced features including IoT connectivity and AI-powered patient compliance monitoring. The market benefits from established medical technology infrastructure and strong government investment in healthcare digitalization that provides enhanced treatment outcomes.

Competitive Landscape of the Intragastric Balloons Market

The intragastric balloons market is characterized by competition among established medical device manufacturers, specialty bariatric companies, and obesity treatment technology suppliers focused on delivering safe, effective, and reliable weight-loss solutions. Companies are investing in clinical research advancement, device safety enhancement, strategic healthcare partnerships, and clinical support services to deliver effective, efficient, and reliable intragastric balloon systems that meet stringent medical and regulatory requirements. Product optimization, clinical validation protocols, and regulatory approval strategies are central to strengthening product portfolios and market presence.

Apollo Endosurgery Inc. leads the market with an 18.0% share, offering comprehensive intragastric balloon solutions with a focus on procedural safety and treatment efficacy for bariatric applications. The company provides specialized endoscopic balloon systems with emphasis on clinical outcomes and comprehensive physician training services. Obalon Therapeutics Inc. focuses on innovative pill-form balloon technologies and patient-friendly administration methods for obesity management serving global markets. Allurion Technologies Inc. delivers established swallowable balloon systems with strong clinical evidence and patient monitoring capabilities.

ReShape Medical Inc. operates with a focus on bringing dual-balloon technologies to specialized bariatric applications and emerging healthcare markets. Spatz3 provides comprehensive adjustable balloon portfolios, including advanced volume modification systems, across multiple patient weight-loss applications and treatment protocols.

Helioscopie specializes in customized European market solutions and safety management systems for clinical facilities with emphasis on regulatory compliance. MEDSIL, Endalis, Lexel Medical, Silimed, and BioEnterics provide reliable manufacturing expertise and technical innovation to enhance market accessibility and healthcare provider access to essential intragastric balloon technologies.

The competitive landscape emphasizes clinical evidence generation, regulatory compliance excellence, and physician training programs as key differentiators. Companies are forming strategic alliances with bariatric surgery centers, obesity medicine specialists, and healthcare systems to expand market reach. Investment in post-market surveillance, real-world evidence studies, and long-term patient outcome tracking strengthens market positioning and supports regulatory requirements across diverse geographic markets.

Key Players in the Intragastric Balloons Market

• Apollo Endosurgery, Inc.
• Obalon Therapeutics, Inc.
• Allurion Technologies, Inc.
• ReShape Medical, Inc.
• Spatz3
• Helioscopie
• MEDSIL
• Endalis
• Lexel Medical
• Silimed
• BioEnterics

Scope of the Report

Items	Values
Quantitative Units (2025)	USD 0.14 Billion
Balloon Type	Single, Dual, Triple
Administration	Endoscopy, Pill Form
Filling Material	Saline-filled, Gas-filled
End Use	Hospitals, Ambulatory Surgical Centers, Clinics
Regions Covered	Asia Pacific, North America, Europe, Latin America, Middle East & Africa
Countries Covered	China, USA, Germany, Japan, India, Brazil, UK, South Korea and 40+ countries
Key Companies Profiled	Apollo Endosurgery Inc., Obalon Therapeutics Inc., Allurion Technologies Inc., ReShape Medical Inc., Spatz3, Helioscopie, MEDSIL, Endalis, Lexel Medical, Silimed, and BioEnterics
Additional Attributes	Dollar sales by balloon type and administration method, regional demand trends, competitive landscape, healthcare provider preferences for specific balloon systems, integration with specialty bariatric care networks, innovations in medical device technologies, safety monitoring, and treatment optimization

Intragastric Balloons Market by Segments

• Balloon Type :

  • Single
  • Dual
  • Triple

• Administration :

  • Endoscopy
  • Pill Form

• Filling Material :

  • Saline-filled
  • Gas-filled

• End Use :

  • Hospitals
  • Ambulatory Surgical Centers
  • Clinics

• Region :

  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • ASEAN
    • Australia & New Zealand
    • Rest of Asia Pacific
  • North America
    • USA
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Nordic
    • BENELUX
    • Rest of Europe
  • Latin America
    • Brazil
    • Argentina
    • Chile
    • Rest of Latin America
  • Middle East & Africa
    • Kingdom of Saudi Arabia
    • Other GCC Countries
    • Turkey
    • South Africa
    • Other African Countries
    • Rest of Middle East & Africa